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ABSTRACT 
Background:  The NHS in England spends over £9 billion on prescription medicines dispensed 
in primary care, of which over two thirds is accounted for by repeat prescriptions.  Recently, 
GPs in England have been urged to limit the duration of repeat prescriptions where clinically 
appropriate to 28 days to reduce wastage and hence contain costs.  However, shorter 
prescriptions will increase transaction costs and thus may not be cost saving.  Furthermore, 
there is evidence to suggest that shorter prescriptions are associated with lower adherence, 
which would be expected to lead to lower clinical benefit.  The objective of this study is to 
estimate the cost-effectiveness of 3-month versus 28-day repeat prescriptions from the 
perspective of the NHS. 
Methods: We adapted three previously developed UK policy-relevant models, incorporating 
transaction (dispensing fees, prescriber time) and drug wastage costs associated with 3-month 
and 28-day prescriptions in three case studies: antihypertensive medications for prevention of 
cardiovascular events; drugs to improve glycaemic control in patients with type 2 diabetes; and 
treatments for depression. 
Results: In all cases, 3-month prescriptions were associated with lower costs and higher 
QALYs than 28-day prescriptions.  This is driven by assumptions that higher adherence leads 
to improved disease control, lower costs and improved QALYs. 
Conclusion: Longer repeat prescriptions may be cost-effective compared with shorter ones.  
However, the quality of the evidence base on which this modelling is based is poor.  Any policy 
rollout should be within the context of a trial such as a stepped-wedge cluster design. 
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Key Points for Decision Makers:  
 Our analyses predict that 3-month repeat prescriptions may be more cost-effective over 
a lifetime than 28-day prescriptions, indicating that policies which encourage shorter 
duration prescriptions to reduce costs are not supported by evidence. 
 We adapted existing decision models for drugs commonly prescribed to patients with 
long-term conditions to account for differences in drug dispensing costs, prescriber 
time, drug wastage and medication adherence. 
 The analyses relied on consistent, but poor quality evidence of a positive association 
between prescription length and adherence.  More rigorous assessment of the long term 
impact of different prescription lengths is warranted to confirm or refute our modelled 
analyses. 
 
 
 
 
 
 
  
  
 
1. INTRODUCTION 
In England, over £9 billion is spent annually by the National Health Service (NHS) on 
prescription medicines dispensed in primary care.[1]  Around two thirds of this expenditure is 
accounted for by repeat prescriptions, which are issued by GPs to treat chronic health 
conditions without the need for a patient consultation.[2] 
Recent policy changes in some areas of England have advised General Practitioners (GPs) to 
reduce the duration of repeat prescriptions issued to patients with chronic health conditions, 
typically from 3-months to 28-days.[3-6]  The rationale for the policy change was to reduce 
medicines waste and thus generate cost savings.  Published estimates, including those of the 
National Audit Office (NAO), suggest that up to £300m of prescription medications are wasted 
in England each year, of which half may be avoidable.[7, 8]  Nevertheless, the policy may have 
overlooked some potential disadvantages of shorter prescriptions, including additional 
transaction costs incurred by the NHS (e.g. through increased GP time to issue prescriptions 
and dispensing fees to pharmacists) and the inconvenience of additional trips to the pharmacy 
(which may lead to reductions in patient satisfaction and additional costs to patients, e.g. related 
to  lost productivity).[9-12]  Furthermore, the relationship between prescription duration and 
adherence to treatment (i.e. whether patients take their drugs as directed by their GP) should 
also be considered, since any detrimental impact on health, including the risk of adverse health 
events, would lead to increased healthcare costs in the longer term. 
A recent systematic review identified consistent (but poor quality) evidence that longer 
prescription duration was associated with increased adherence but increased wastage.[13]  An 
analysis of UK primary care data confirmed the positive relationship between prescription 
duration and wastage.[14]  However, this also showed that reductions in transaction costs 
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associated with longer prescriptions more than compensated for the costs of increased wastage 
(at least in the case studies examined).  The review[13] noted (1) a shortage of studies 
examining the long term relationship between prescription duration and health outcomes (mean 
follow-up of previous studies was 20.3 months), (2) that existing studies were entirely US 
based and so of questionable relevance to the UK setting, (3) only one examined any impact 
on health outcomes,[15] and (4), none reported outcomes in terms of QALYs gained.   
Therefore, the purpose of this paper is to estimate the longer term costs and health 
consequences and hence incremental cost-effectiveness associated with 3-month and 28-day 
repeat prescriptions for patients with stable, chronic conditions requiring one or more repeat 
prescriptions in the primary care setting.   
 
2. METHODS 
We selected three case studies of drugs typically prescribed in primary care for chronic, stable 
conditions.  These were (1) antihypertensive medications for prevention of cardiovascular 
events in patients with essential hypertension, (2) metformin to improve glycaemic control in 
patients with type 2 diabetes, and (3) selective serotonin reuptake inhibitors (SSRIs) for 
depression. 
We first identified and then adapted existing decision analytic models used to assess the clinical 
and cost-effectiveness of relevant pharmaceutical products by the National Institute for Health 
and Care Excellence (NICE).  We then identified data on (1) the relationship between 
prescription length and adherence in patients with chronic health conditions (from the 
systematic review [13]), (2) the relative treatment effects of the drugs vs placebo (where 
existing analyses did not compare versus placebo) (from relevant NICE guidance), (3) 
  
transactions costs (dispensing fees and prescriber time) and (4) cost of drug wastage (from an 
analysis of UK primary care data [14]).   
Models were adapted to calculate the expected cost and QALYs gained from 3-month or 28-
day repeat prescriptions.  A general overview is shown in Figure 1; the long term cost and 
QALYs associated with a particular treatment were assumed to represent perfect adherence and 
those of placebo to represent zero adherence.  Given that the systematic review[13] showed 3-
month repeat prescriptions were associated with higher adherence than 28-day prescriptions, 
in the absence of evidence to the contrary, we assumed the 3-month repeat prescriptions would 
yield the expected cost and QALYs associated with perfect adherence (i.e. p=1 in Figure 1), 
and 28-day be equal to those multiplied by the relative risk of adherence.  Plausible values for 
the relative risk for each of the three groups of commonly prescribed medications were 
extracted from studies identified in the systematic review that had examined medications which 
could be reasonably categorised into those three groups. [13] Where there was more than one 
estimate, or a range of estimates, these were subsequently used in sensitivity analyses. 
A summary of the methods used in each case study is provided in Table 1.  Incremental cost 
effectiveness ratios (ICERs) were calculated (based on the incremental costs and QALYs of 
treatment with 3-month versus 28-day prescriptions).  Net benefit and incremental net benefit 
(INB) were also reported.  This assumes a threshold value of the decision maker’s willingness 
to pay for a QALY of £20,000 (the lower end of the cost effectiveness threshold over which 
treatments are less likely to be recommended for use in the NHS).[16]  The perspective of the 
evaluation was costs to the NHS in England and all cost data are reported in 2015/6 British 
Pounds Sterling.  Costs were inflated when necessary to 2015/6 levels using the Personal Social 
Services Research Unit (PSSRU) Hospital and Community Health Service indices.[17]   
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Specific methods for each case-study follow, with summaries of the original source models 
provided in Table 2, and of the identified data and key assumptions in Table 3.    Some 
additional details for is also provided in Appendices 1, 2 and 3 (Electronic Supplementary 
Materials). 
 
2.1 CASE STUDY 1: Antihypertensive medications for prevention of cardiovascular 
events in patients with essential hypertension 
Stage 1: Identify decision model 
Relevant NICE guidelines on pharmacological interventions for adults with essential 
hypertension were reviewed.  The most recent NICE guidance (CG127, updated 2011) included 
a Markov model which assessed the cost effectiveness of four groups of alternative 
antihypertensive medications (angiotensin converting enzyme inhibitors [ACEIs]/angiotensin 
II receptor blockers [ARBs], beta blockers, calcium channel blockers, thiazide type diuretics) 
and a ‘no treatment’ comparator  (Table 2).[18]   
The model has seven discrete health states (event free/well, myocardial infarction (MI), 
unstable angina, stroke, diabetes, heart failure and death, Figure 2).  The likelihood of moving 
between states during each model cycle is determined by transition probabilities which vary 
according to patient characteristics (e.g. age, sex, ethnicity and baseline health event risks) and 
the prescribed medication.  Transition probabilities in the ‘no treatment’ arm as well as relative 
risks for each treatment had been extracted from relevant literature.  Health state utilities had 
been derived from published studies and used to calculate QALYs.  Annual costs associated 
with each health state (from the NHS perspective), and the costs of medications, had been 
  
identified from various sources (e.g. British National Formulary, BNF) and used as inputs in 
the model. (Table 2).[18]   
Stage 2:  Identify additional data 
In the systematic review,[13] two studies by Hermes et al. 2010 and Taitel et al. 2012 reported 
the relative risk of being adherent for longer versus shorter duration prescriptions for 
antihypertensive medications.[19, 20]  No primary studies nor decision models were identified 
examining the relationship between prescription length (or adherence) and health outcomes. 
[13] 
It was not necessary to identify additional input data on the costs and health consequences of 
zero adherence since the source model included a ‘no treatment’/placebo comparator.  The cost 
of dispensing fees identified from the latest NHS Drug Tariff [21] and the cost of prescriber 
time and drug wastage associated with different duration prescriptions for antihypertensive 
medications were identified in the analysis of UK primary care data (Table 3).[14] 
Stage 3:  Adapt existing model 
Modifications to the structure of the source model were not required as it already examined the 
costs and consequences of the main groups of antihypertensive interventions currently 
prescribed in general practice, and included a ‘no treatment’ comparator. 
First, the model was replicated and run to assess the lifetime expected costs and QALYs 
associated with a weighted average of antihypertensive treatments and with placebo (i.e. 
representing ‘perfect’ adherence with antihypertensives and zero adherence as illustrated in 
Figure 1).  As in the base case analysis used in the source model, the cohort used in the analysis 
was based on a 65-year-old male with an annual cardiovascular disease risk of 2%, heart failure 
risk of 1% and diabetes risk of 1.1%.  Second, we conducted two alternative analyses to 
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incorporate different adherence levels associated with 3-month and 28-day prescriptions, 
described in more detail below. 
Antihypertensives versus ‘no treatment’ 
The source model estimated a cost of £5,185 and 9.57 QALYs for ‘no treatment’.  A ‘typical 
treatment’ comparator was created as a weighted average of the costs and QALYs associated 
with each of the four groups of antihypertensive medications.  The weights were assigned from 
total numbers of items dispensed in the community in 2014 (the latest available data) for each 
antihypertensive class (Appendix 1, Table A1). [22]   For this ‘typical treatment’ comparator, 
the total costs were £4,563 and 10.16 QALYs.  This yielded an ICER of £-1,062 (treatment 
dominates ‘no treatment’, Table 4). 
3-month versus 28-day prescribing of antihypertensives 
We conducted two analyses representing alternative scenarios.  In both cases we first added in 
the transaction and drug wastage costs (Table 3).  For the 3-month arm this equated to an extra 
£21.01 per annum (=[dispensing fees (£0.90) + prescriber time (£3.77) + wastage costs 
(£0.51)]×[365/90]), and in the 28-day arm, £61.68 (=[dispensing fees (£0.90) + prescriber time 
(£3.76) + wastage costs (£0.07)]×[365/28]).  
In the first analysis, we assumed the costs and outcomes associated with 3-month prescriptions 
were equal to the cost and outcomes associated with ‘weighted treatment’, i.e. £4,563 and 10.16 
QALYs, (to which the transaction and drug wastage costs were added).  In the 28-day arm, the 
total costs and QALYs were a weighted average of the QALYs in the ‘typical treatment’ and 
the ‘no treatment’ comparators, as described in the Methods section.  The weighted average 
was calculated using evidence from the studies by Hermes et al. 2010 and Taitel et al. 2012 on 
the relationship between prescription length and adherence which reported relative risks of 0.92 
  
and 0.85 respectively.[19, 20]  We report analyses using both sources separately, as well as 
further analyses using the highest and lowest 95% confidence limits of the two sources (lowest 
lower bound, Taitel et al. 2012, RR=0.846, highest upper bound Hermes et al. 2010, RR=0.928) 
to provide a plausible range of ICERs and INB. 
In the second analysis, instead of adjusting overall costs and QALYs, we adjusted the relative 
risks of the transition probabilities by the adherence.  For example, the relative risk of MI 
assumed with 3-month prescriptions for beta-blockers is 0.86 (Appendix 1, Table A2).  The 
relative adherence with 28-day vs 3-month prescriptions is 0.85,[20] so the relative risk of MI 
with 28-day prescriptions is 0.88 (=1-[1-0.86]×0.85). 
2.2 CASE STUDY 2: Metformin to improve glycaemic control in patients with type 2 
diabetes 
Stage 1 and 2: Identify decision model and additional data 
Details of model and data identification (stages 1 and 2 of Table 1) are in Appendix 2.   
Stage 3: Adapt existing model.  
We focused on the impact of different prescription lengths at the initial therapy stage (people 
failing to manage their condition on diet and exercise alone) comparing metformin with 
placebo (two of the seven comparators in the original model).  Metformin was chosen for use 
in this case study as it is current first-line practice.  The existing structure of the model and all 
model inputs remained unchanged, since the identified model already examined the costs and 
consequences of a wide range of pharmacological interventions for type 2 diabetes which are 
currently prescribed in general practice in the UK. 
Metformin versus ‘no treatment’ 
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Lifetime costs and QALYs for metformin, estimated using the original source model were 
£19,90 and 9.033 respectively, compared with £20,722 and 8.912 for placebo (assumed to 
represent no treatment) (Table 5). Metformin therefore dominates placebo.  These results were 
driven by higher risk of diabetes-related complications (including amputation, blindness, renal 
failure, heart disease and stroke) and higher treatment costs due to more rapid progression to 
later-stage intensification therapies (where patients received >1 non-insulin based therapy) 
with placebo. 
3-month versus 28-day prescribing of metformin 
As per case study 1, we assumed 3-month prescriptions yielded equivalent costs and outcomes 
to the metformin treatment arm in the source model (i.e. p=1 as per Figure 1).  To this was 
added additional annual transactional and drug wastage costs for 3.8 years, the period of time 
the average patient received initial treatment (monotherapy, where metformin was the only 
antidiabetic drug). 
For the 28-day prescriptions, we took a weighted average of the costs and QALYs of the 
metformin and placebo arms according to the relative risk of being adherent reported by 
Hermes and Taitel, which were 0.891 and 0.863 respectively.[19, 20]  These are reported as 
two separate scenario analyses. The total costs and QALYs for the 28-day prescriptions in the 
first scenario are calculated as 0.891×Metformin arm costs or QALYs + 0.109×placebo arm 
costs or QALYs.  To these calculated total costs were added the additional transaction and drug 
wastage costs for the average initial treatment period (3.64 years in the first scenario).  As per 
case study 1, we also explored the lower and upper 95% confidence limits (lowest lower bound, 
Taitel, RR=0.851, highest upper bound Hermes, RR=0.926). 
2.3 CASE STUDY 3: Selective serotonin reuptake inhibitors (SSRIs) for depression 
  
Stage 1 and 2: Identify decision model and additional data 
Details of model and data identification (stages 1 and 2 of Table 1) are in Appendix 3.   
Stage 3: Adapt existing model.  
In this case study, we maintained the overall model structure since the identified model had 
recently been updated by NICE in 2016 and already examined the costs and consequences of 
antidepressants currently prescribed in general practice.  However, whereas the original 
treatment arms emanating from the decision node in the model were two comparable 
pharmacological interventions (or a pharmacological intervention with and without CBT), in 
our adapted model (Appendix 3, Figure A3.1), we substituted instead 3-month and 28-day 
prescribing of a ‘typical’ SSRI. 
The unit cost data was based on a weighted average of the costs associated with ten (generic 
and branded) SSRIs.  The weighted average was calculated using unit cost data from the 
Prescription Cost Analysis (published by NHS England) which showed the total number of 
items dispensed in the community in 2014 for each group of medications.[22] For the 3-month 
and 28-day arms of the decision tree, we added the appropriate transaction and wastage costs 
to these (weighted average) SSRI unit costs. 
The health consequence data for our ‘typical’ SSRI was based on data reported in the NICE 
clinical evidence review on the absolute risk of dropout, no remission and relapse for a placebo 
arm, and the relative risk for an escitalopram treatment arm.  These data were used to calculate 
the probability nodes in the decision tree where the placebo arm represented our zero adherence 
scenario and the escitalopram treatment arm represented our perfect adherence scenario 
(Appendix 3, Table A3.1).  Since the NICE guideline development group concluded that there 
was sufficient doubt about the clinical importance of differences between antidepressant 
14 
 
treatments to not justify the development of recommendations for specific drugs,[23] we did 
not examine data on the relative efficacy of other antidepressants compared to escitalopram. 
Replicating the approach taken by NICE using the source model, we reported the model outputs 
in terms of the total costs and QALYs of the two arms of the decision tree for two separate 
cohorts of 100 patients with moderate and severe depression (Table 6). 
SSRIs versus placebo 
For patients with moderate and severe depression, SSRI treatment was less costly (£1,907.79 
versus £2,039.94 per patient in the case of moderate depression) than placebo with higher 
QALY gains (0.63 versus 0.61 in the case of moderate depression, Table 6).  The INB per 
patient for moderate and severe depression was estimated at £467 and £529 respectively. 
3-month versus 28-day prescribing of SSRIs 
As per the other case studies, costs and outcomes for the 3-month prescriptions are assumed to 
be the same as the treatment arm.  Those for the 28-day treatment arm were calculated using a 
weighted average of the cost and QALYs associated with perfect and zero adherence (based on 
the evidence from studies on the relationship between prescription length and adherence 
identified in the systematic review [13]). 
Two relevant studies, by Pfeiffer and Taitel,[20, 24] reported relative risks of 0.542 and 0.748 
respectively.  We reported results with these point estimates separately, as well as at the lowest 
lower 95% confidence limit (Pfeiffer, RR=0.540) and highest higher limit (Taitel, RR=0.780) 
to define a plausible range of ICERs and INB. 
 
3. RESULTS 
  
 
In all three case studies for all scenarios, longer prescriptions were both cost-saving and led to 
higher QALYs gained.  In case study 1 (antihypertensives), the INB per patient ranged from 
£1,470 to £2,571 (Table 4).  In case study 2 (metformin), 3-month prescriptions were less costly 
and yielded higher QALYs than 28-day prescriptions, with expected INB per patient of 
between £312 and £555 (Table 5).  Finally, in case study 3 (SSRIs), for both moderate and 
severe depression, the ICERs remained negative (3-month prescriptions were cost saving and 
QALY-enhancing).  The INB per patient ranged between £378 and £496 for moderate 
depression and £427 and £560 for severe. 
 
4. DISCUSSION 
 
Principal findings 
The main finding was that longer, 3-month repeat prescriptions are associated with lower 
lifetime costs and higher QALYs when compared with shorter, 28-day prescriptions.  The main 
driver for this finding was improved adherence in the 3-month scenarios, which was grounded 
in the evidence from all studies of the relationship between prescription duration and adherence 
identified in the systematic review.[13]  The lower transaction and drug wastage costs reported 
in the analysis of primary care data[14] also contributed to the finding.  Although these 
immediate cost savings are smaller in magnitude than the longer term benefits arising from 
improved adherence, they might nonetheless be more pertinent to those making prescribing 
decisions.  Furthermore, it is probable that patients would favour longer prescriptions, at least 
from the perspective of limiting the frequency of pharmacy visits. 
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As a result, 3-month prescriptions dominate 28-day prescriptions, with positive INB associated 
with the 3-month prescriptions.  For example, the plausible range of INB (to the NHS) per 
patient with hypertension receiving treatment for the secondary prevention of cardiovascular 
events was £1,575 to £2,571.  Data from the Health Survey for England shows that 14% of 
men and 15% of women are currently prescribed antihypertensives specifically for 
hypertension.[25]  Thus there may be significant potential for (long term) cost savings and 
health gain if these patients were routinely issued 3-month duration repeat prescriptions.  This 
finding was consistent across all three case studies, despite differences in the nature of the 
treatments.  Whereas two case studies focused on the prevention of future ill-health (e.g. 
cardiovascular events), so increased adherence reduced the expected costs of health 
complications later in life, the other case study examined SSRI treatment for moderate and 
severe depression, a chronic or episodic condition.  In this case, lower healthcare costs were 
associated with longer duration prescriptions due to reductions in, for example, the likelihood 
of requiring additional care during the initial treatment phase as a hospital inpatient. 
Our remit was to explore the implications of longer prescription lengths for chronic stable 
disease.  Such treatments tend to be dominant (both less expensive and yielding greater 
QALYs) compared with placebo as they tend to be low cost drugs with potential to prevent 
significant life-changing events such as MI or stroke in the future.  This was indeed the case in 
our three case studies.  For non-dominant examples, as long as perfect adherence is cost-
effective, any partial adherence will also be cost-effective conditional on a linear dose/response 
relationship.  Exploration of this is beyond the scope of this analysis, but drugs requiring close 
to perfect compliance for any effect to be observed are unlikely to be suitable for longer 
prescriptions on cost-effectiveness grounds. 
Comparison with existing studies 
  
In a recent economic evaluation of a pharmacist-led intervention which supports people starting 
new medications for long term conditions, decision analytic models were used to assess the 
lifetime cost and health consequences arising from improved adherence.[26] However, to the 
best of the authors’ knowledge this is the first study to use decision modelling to assess the 
impact of prescription duration on longer term costs and QALYs.   
A number of other observational studies have examined the cost impact of different 
prescription lengths.  A negative relationship between costs and prescription length was found 
in four of five studies identified [20, 27-29] but the relationship arose for different reasons.  
The four observing a negative relationship had examined the costs (to third party payers in the 
US) over a short time horizon.  The cost savings arose from reductions in administrative costs 
of prescribing medication (e.g. dispensing fees).  However, these studies did not account for 
changes in wider healthcare expenditure which would result, particularly in the longer term, 
from the changes in health status associated with different adherence levels.   
The fifth identified study did include those wider costs and showed a positive relationship 
between prescription length and costs.[30]  One explanation could be that healthcare 
expenditures were examined only over a short time horizon, whereas (two of) the case studies 
presented in this article examined lifetime costs, focusing on prevention of future 
cardiovascular events.  It should also be noted that all the previous studies were US based and 
generally from a particular payer’s perspective (e.g. Veterans Affairs or Medicaid) which may 
not be directly comparable to the UK setting. 
Limitations 
The three case studies presented in this article are based on relatively straightforward adaptions 
of existing, good quality decision models, all of which have been used to inform policy in the 
recent past.  We chose these models (rather than conducting a systematic review of other 
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models) as they by definition met NICE’s quality criteria and had already been used to inform 
policy.  Basing our analyses on these models thus ensured the case studies were comparable 
with NICE guidance and hence most policy relevant.  Limitations inherent to the specific 
models are discussed in full detail in the respective guidelines.  Therefore, the remainder of 
this section addresses limitations related to the model adaptations which were made in this 
study. 
First, our findings rely on the positive relationship between prescription length and adherence 
which was based on studies identified in a systematic review.[13]  Whilst all the evidence was 
consistent, the studies were observational studies, rather than randomised experimental studies, 
and so are at high risk of bias.   
Second, in the absence of data to the contrary, the model adaptations relied on two key 
assumptions: (i.) treatment effects observed in model active and placebo (no treatment) arms 
of clinical trials were assumed to represent the maximum effect comparing perfect and zero 
adherence and (ii.) a linear dose response curve was assumed, thus 50% adherence would 
generate 50% of the treatment effect.  However, since we consistently identified a positive INB 
associated with longer prescription durations, any change in these assumptions would affect 
only the magnitude of QALY gains, cost savings and INB.  The likelihood that longer 
prescriptions represent a cost-effective choice would not be affected. 
Third, as is common in all decision models which include a ‘no treatment’ arm, it was necessary 
to assume that health outcome data from the ‘placebo’ arm of clinical trials is equivalent to ‘no 
treatment.’ However, the placebo effect may lead to an overestimation of the QALYs 
associated with no treatment. Consequently, the health gain arising from increased adherence 
in longer prescription durations may have been underestimated. 
  
Other limitations were that we assumed adherence was constant over the period of the analysis, 
and whilst the study took an NHS perspective, any revenue due to the NHS from prescription 
charges was excluded.  However, patients with diabetes are exempt from the prescription 
charge, and almost 90% of prescriptions dispensed in the community in England do not attract 
any charge, therefore any revenue would be minimal and thus unlikely to change the results of 
this study.[31]  
 
5. CONCLUSION 
The finding that longer prescriptions may be cost saving to the NHS indicates that the recent 
policy of encouraging GPs to prescribe 28-day duration prescriptions is not supported by the 
evidence.  Whilst this study accounted for the cost savings from reduced medicine waste 
associated with 28-day prescription duration, these short term savings were outweighed by 
additional transaction and drug wastage costs and longer term healthcare costs arising from 
reduced adherence.  However, our results must be considered with due caution as they rely on 
the evidence suggesting a positive association between prescription length and adherence; the 
observational nature of the studies means they are at high risk of bias.  In order to identify an 
optimal prescription length, the exact nature of this relationship needs further examination (not 
least since it is unlikely to be linear nor constant between different populations and disease 
areas).  Hence we suggest implementing different duration prescriptions only within, for 
example, a stepped-wedge cluster randomised controlled trial design to inform a more rigorous 
assessment of the costs and/or (short term) health impacts of different duration prescriptions. 
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Figures 
 
 
Figure 1:  Decision tree to illustrate the general approach to modelling 
 
 
 
 
p = Probability of perfect adherence in active treatment arm of existing model (in this study it is assumed 
that p=1) 
RR=Relative risk of being adherent with a 28-day prescription compared to 3-month prescription. 
  
  
Figure 2:  Schematic representation of the Markov model used in Case Study 1: 
Antihypertensive medications for prevention of cardiovascular events in patients with essential 
hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arrows represent the possible transitions between each of the health states.  Diagram based on model 
description reported in NICE guidance (CG127, updated 2011).[18]   
Well:   
event free 
Myocardial 
infarction 
Diabetes 
Stroke 
Death 
Heart failure 
Unstable 
angina 
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Tables 
 
Table 1:  An overview of the methodological approach used in the three case studies 
METHODS 
Stage 1 Appropriate decision models were identified.  These had been used by NICE to assess 
the cost-effectiveness of relevant medications.  The selected models are summarised 
in Table 2. 
Stage 2 Additional data was identified (if not already included in the original decision model) 
as follows: 
- (i.) the relative treatment effects of treatment versus placebo 
- (ii.) relationship between adherence and health consequences 
- (iii.) relationship between prescription length and adherence 
- (iv.) transaction costs (dispensing fees and prescriber time) 
- (v.) cost of drug wastage 
This data is described for each case study in Table 3. 
Stage 3 The decision model was adapted.  Drawing on the data identified in Stage 1, the input 
parameters and/or model outputs of the identified decision model were adjusted to 
account for different costs, QALYs and adherence associated with no treatment and 
treatment with different prescription duration 
RESULTS 
 
Health consequences, costs, ICERs and Incremental net benefit (INB) were reported for: 
- treatment compared to placebo 
- treatment with 3-month compared to 28-day prescription duration 
The results for each case study are reported in Tables 4, 5 and 6. 
 
 
  
  
Table 2:  Key characteristics of the source models 
 Case Study 1: 
Antihypertensive medications 
for prevention of 
cardiovascular events in 
patients with essential 
hypertension 
Case Study 2: 
Drugs for prevention of 
cardiovascular events in 
patients with type 2 diabetes 
Case Study 3: 
Selective serotonin reuptake 
inhibitors (SSRIs) for 
depression 
Type of model Markov model with 6 month 
cycles and 2,000 iterations 
Patient-level simulation model 
with 12 month cycles and 1,000 
iterations 
Decision tree 
Source of model NICE clinical guidance (CG127) 
[18] 
The original model is the 
UKPDS model.  It was adapted 
by NICE for clinical guidance 
(NG28) [32]  
NICE clinical guidance (CG90) 
[33] 
Time horizon Lifetime 40 years (equivalent to lifetime, 
given the average starting age 
was >60 years) 
14-15 months (this included a 2-
3 month acute treatment phase, a 
6 month maintenance treatment 
phase, and a 6 month follow-up 
phase) 
Comparators Four groups of alternative anti-
hypertensive drugs 
(ACEIs/ARBs, beta-blockers, 
calcium-channel blockers, 
thiazide-type diuretics) and no 
treatment 
The model was run separately for 
three discrete stages of disease 
progression (initial therapy, first 
intensification and second 
intensification).  In each stage at 
least seven comparators were 
modelled (e.g., for initial 
therapy, this included placebo 
and metformin) 
One analysis focused on 
pharmacological interventions 
(ten different antidepressants 
were assessed).  Another 
analysis focused on combination 
therapy (CBT combined with 
SSRI treatment compared to 
SSRI treatment alone) 
Selected base-case 
patient 
characteristics 
65-year old male with essential 
hypertension (2% cardiovascular 
disease risk, 1% heart failure risk 
and 1.1% diabetes risk) 
Newly diagnosed patients with 
type 2 diabetes seeking initial 
therapy.  57.1% were male and 
the mean age was 59.8 years 
Patients with moderate to severe 
depression 
Perspective NHS for costs and patients for 
health outcomes 
NHS for costs and patients for 
health outcomes 
NHS for costs and patients for 
health outcomes 
Health outcome QALYs which reflected 
prevention of cardiovascular 
events (non-fatal unstable 
angina, myocardial infarction, 
heart failure and stroke, and 
cardiovascular-related deaths) 
and side effects (onset of heart 
failure and diabetes) 
QALYs which reflected the 
impact of treatment on the first 
occurrence of seven diabetes-
related complications (fatal or 
non-fatal MI, other IHD, stroke, 
heart failure, amputation, renal 
failure and eye disease measured 
in terms of blindness in one eye) 
and death.  All based on data 
from UKPDS RCT.[34] 
QALYs (utility scores were 
based on a study by Sapin et al. 
2004).[35] 
Key clinical input 
parameters 
Baseline risks were identified 
from a range of sources.[18] 
Treatment effects on HbA1c, 
weight, hypoglycaemic episodes 
and treatment drop outs due to 
intolerance were taken from a 
clinical review network meta-
analysis ) [32] 
Odds and probabilities of drop 
out (after 2-3 months), remission 
(after 8-9 months) and relapse 
(after 14-15 months) were 
identified in a literature review 
and through expert opinion. (see 
Appendix Table A3.2) 
Discounting 3.5% for costs and QALYs 
 
3.5% for costs and QALYs 3.5% for costs and QALYs 
    
Key limitations of 
model 
No probabilistic sensitivity 
analyses were reported 
No placebo treatment group was 
included in the first and second 
intensification of treatment.  
Patients on initial treatments thus 
moved to metformin-
sulfonylurea (first 
intensification) then metformin-
NPH insulin (second 
intensification) after a period of 
time 
Treatment continued for only 9 
months with follow-up for a 
further 6 months.  Although this 
model was developed to inform 
current NICE guidance and is 
consistent with other SSRI 
studies (see Cipriani et al. 2009 
[36]), this may not reflect current 
clinical practice and may not 
capture all costs and outcomes 
 
 
Table 3: Identified data and key assumptions used in the adapted models 
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 Case Study 1: 
Antihypertensive 
medications for prevention 
of cardiovascular events in 
patients with essential 
hypertension 
Case Study 2: 
Drugs for prevention of 
cardiovascular events in 
patients with type 2 diabetes 
Case Study 3: 
Selective serotonin reuptake 
inhibitors (SSRIs) for 
depression 
(i.) the relative 
treatment effects of 
treatment versus 
placebo 
 
The source model 
(NICE CG127), which 
included a ‘No 
treatment’ comparator  
The source model 
(NICE NG28), which 
included a ‘placebo’ 
comparator  
A clinical evidence 
review published 
alongside NICE CG90 
which included 
evidence on treatment 
versus placebo  
 
(ii.) Relationship 
between adherence and 
health consequences 
 
Assumed to be linear since no relevant evidence was identified 
 
(iii.) Relationship 
between prescription 
length and adherence 
 
Studies by Hermes et 
al. 2010 (RR=0.92) and 
Taitel et al. 2012 
(RR=0.85)[19, 20]  
identified in systematic 
review[13] 
Studies by Hermes et 
al. 2010 (RR=0.891) 
and Taitel et al. 2012 
(RR=0.863)[19, 20] 
identified in systematic 
review[13]  
Studies by Taitel et al. 
2012 (RR=0.748) and 
Pfeiffer et al. 
(RR=0.542) [20, 24]  
identified in systematic 
review[13] 
 
(iv.) Transaction costs 
 
Data reported in the analysis of UK primary care data [14]  
 
Dispensing fees £0.90 
Prescriber time £3.77 (in 3 month 
scenario) 
£3.76 (28 days) 
£3.55 (in 3 month 
scenario) 
£3.54 (28 days) 
£3.18 (in 3 month 
scenario) 
£3.23 (28 days) 
 
(v.) Cost of drug 
wastage 
 
Data reported in the analysis of UK primary care data [14] 
£0.51 (in 3 month 
scenario) 
£0.07 (28 days) 
£1.37 (in 3 month 
scenario) 
£0.33 (28 days) 
£0.43 (in 3 month 
scenario) 
£0.21 (28 days) 
RR = relative risk of being adherent.  Costs are reported in 2015/6 pounds. 
 
 
  
Table 4:  Results (Case study 1: Antihypertensive medications for prevention of 
cardiovascular events in patients with essential hypertension) 
 
 
Total lifetime 
cost 
Total 
lifetime 
QALYs 
Net benefit 
Incremental analysis 
Incremental 
net benefit Costs QALYs ICER 
Source model:  No intervention and weighted treatment comparators 
No 
intervention 
£5,185 
9.57 
£188,762 
NA NA NA NA 
Typical 
treatment 
£4,563 
10.16 
£201,245 
-£622 0.59 -£1,062 £12,483 
First approach1 based on Hermes (RR=0.916) 
28 day  £5,485 10.12 £199,374 NA NA NA NA 
90 day 
 
£4,859 
10.16 
£200,949 
-£626 0.05 
-£13,373   £1,575  
First approach1 based on Taitel (RR=0.851) 
28 day  £5,543 10.07 £198,485 NA NA NA NA 
90 day £4,859 10.16 £200,949 -£684 0.09 -£7,794   £2,463  
Second approach2 based on Hermes (RR=0.916) 
28 day  £5,488 10.10 £199,297 NA NA NA NA 
90 day £4,859 10.16 £200,949 -£629 0.05 -£12,478   £1,652  
Second approach2 based on Taitel (RR=0.851) 
28 day  £5,549 10.06 £198,378 NA NA NA NA 
90 day £4,859 10.16 £200,949 -£690 0.09 -£7,432   £2,571  
SENSITIVITY ANALYSIS 
First approach1 based on upper-bound of Hermes relative risk estimate (RR=0.928) 
28 day  £5,478 10.11 £199,478 NA NA NA NA 
90 day £4,859 10.16 £200,949 -£619 0.04 -£14,742   £1,470  
First approach1 based on lower-bound of Taitel relative risk estimate (RR=0.846) 
28 day £5,547 10.07 £198,437 NA NA NA NA 
90 day £4,859 10.16 £200,949 -£687 0.09 -£7,634   £2,512  
NA = not applicable, RR = relative risk of being adherent.  Costs are reported in 2015/6 pounds. 
1The first approach involved adapting the cost and QALY outputs of the model to account for different 
adherence levels. 
2The second approach involved adjusting model inputs to account for different adherence levels (i.e. 
the relative treatment effects, versus no treatment, for each health state). 
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Table 5:  Results (Case study 2: Drugs for prevention of cardiovascular events in patients with type 2 diabetes):  Mean years on initial 
treatment, lifetime costs, QALYs and incremental analysis  
 
Years on initial 
treatment1 
Total lifetime 
cost 
The total cost includes 
Total lifetime 
QALYs 
Incremental analysis 
Incremental net 
benefit UKPDS2 
Treatment 
costs 
Additional 
costs3 
Costs QALYs ICER 
Placebo and treatment arms in  source model 
Placebo 2.30 £20,722 £14,223 £5,664 NA 8.912  NA  NA  NA   NA  
Treatment (Metformin) 3.80 £19,900 £14,155 £5,016 NA 9.033 -£822  0.121 -£6,791   £3,274  
28-day and 3-month prescribing -  based on Hermes (RR=0.891) 
28 day 3.64 £20,060 £14,163 £5,087 £70 9.02  NA  NA  NA   NA  
3 month 3.80 £19,939 £14,155 £5,016 £39 9.033 -£160  0.013 -£9,134   £429  
28-day and 3-month prescribing-  based on Taitel (RR=0.863) 
28 day 3.59 £20,082 £14,165 £5,105 £69 9.016  NA  NA  NA   NA  
3 month 3.80 £19,939 £14,155 £5,016 £39 9.033 -£181  0.017 -£8,613   £518  
SENSITIVITY ANALYSIS 
28-day and 3-month prescribing -  based on upper-bound of Hermes (RR=0.926) 
28 day 3.64 £20,032 £14,160 £5,063 £71 9.02  NA  NA  NA   NA  
3 month 3.80 £19,939 £14,155 £5,016 £39 9.033 -£132  0.009 -£10,396   £312  
28-day and 3-month prescribing- based on lower-bound of Taitel (RR=0.851) 
28 day 3.59 £20,091 £14,165 £5,112 £69 9.016  NA  NA  NA   NA  
3 month 3.80 £19,939 £14,155 £5,016 £39 9.033 -£192  0.018 -£8,454   £555  
NA = not applicable 
RR = relative risk 
Costs are reported in 2015/6 pounds. 
1 All initial treatments intensified to metformin-sulfonylurea (first intensification) then metformin-NPH insulin (second intensification) after a period of time. 
2 UKPDS: costs incurred within UKPDS Outcomes Model 1 as a result of survival time and long term complications 
3 Additional costs are the sum of transactional (dispensing fees and prescriber time) and drug wastage costs for the period of time the average patient received initial treatment 
  
  
Table 6:  Results (Case study 3:  Selective serotonin reuptake inhibitors (SSRIs) for depression):  Lifetime costs, QALYs and incremental 
analysis for patients with moderate and severe depression  
 Moderate depression Severe depression 
Total 
costs 
Total 
QALYs 
Net benefit Incremental analysis Total costs Total 
QALYs 
Net benefit Incremental analysis 
Costs QALYs ICER INB Costs QALYs ICER INB 
Placebo and ‘typical treatment’ arms1 
Placebo £203,994 61.13 £1,034,838 n/a  £228,470  49.38  £772,283  n/a 
Treatment £190,779 62.78 £1,081,502 -£13,215  1.65 -£8,006  £46,664   £215,799  51.37  £825,185  -£12,671  1.99 -£6,384   
£52,902  
28 day and 3 month prescribing scenarios –Based on Taitel (RR=0.748) 
28 day £222,910 62.36 £1,040,937 n/a  £251,288  50.87  £779,552  n/a 
3 month 
£191,966 62.78 £1,080,315 -£30,944  0.42 -£18,749   £39,379   £216,984  51.37  £823,998  -£34,303  0.5 -£17,281   
£44,447  
28 day and 3 month prescribing scenarios –Based on Pfeiffer (RR=0.542) 
28 day £226,157 62.02 £1,030,809 n/a  £254,408  50.46  £768,157  n/a 
3 month 
£191,966 62.78 £1,080,315 -£     34,192  0.76 -£     20,716   £     49,506   £     216,984  51.37  £     823,998  
-£     
37,422  0.91 
-£     
18,852  
 £     
55,841  
SENSITIVITY ANALYSIS 
28 day and 3 month prescribing scenarios –Based on upper-bound of Taitel relative risk estimate (RR=0.780) 
28 day £222,408 62.42 £1,042,503 n/a  £     250,805  50.93  £     781,315  n/a 
3 month 
£191,966 62.78 £1,080,315 -£     30,443  0.36 -£     18,444   £     37,812   £     216,984  51.37  £     823,998  
-£     
33,820  0.44 
-£     
17,038  
 £     
42,683  
28 day and 3 month prescribing scenarios –Based on lower-bound of Pfeiffer relative risk estimate (RR=0.540) 
28 day £226,191 62.02 £1,030,702 n/a  £     254,440  50.45  £     768,037  n/a 
3 month 
£191,966 62.78 £1,080,315 -£     34,225  0.76 -£     20,736   £     49,612   £     216,984  51.37  £     823,998  
-£     
37,455  0.91 
-£     
18,869  
 £     
55,961  
The results are reported for a cohort of 100 patients.  Costs are reported in 2015/6 pounds. 
1 The ‘typical treatment’ comparator included a weighted average of the costs associated with ten groups of antidepressant medications based on Prescription Cost Analysis 
figures published by NHS England which show the total number of items dispensed in the community (the proportions were for 2014, the most recent available data).  The 
proportions calculated were:  Citalopram (0.341), Duloxetine (0.034), Escitlopram (0.022), Fluoxetine (0.150), Fluvoxamine (0.001), Mirtazapine (0.146), Paroxetine (0.036), 
Reboxetine (0.001), Sertraline (0.187), Venlafaxine (0.081). 
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